Channel Screening Report 2026-2032: Fluorescence Imaging, hERG Testing & Preclinical Discovery
公開 2026/04/07 15:36
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report *"Ion Channel Screening Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032"*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Ion Channel Screening Service market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Ion Channel Screening Service was estimated to be worth US$ 518 million in 2025 and is projected to reach US$ 939 million, growing at a CAGR of 9.0% from 2026 to 2032. The Ion Channel Screening Service is a professional service based on advanced biotechnological approaches. It employs cutting-edge techniques such as cellular electrophysiological recording and fluorescence imaging to systematically test a large number of compounds or biomolecules. By analyzing their effects on the opening, closing states, and ion permeability of ion channels, it precisely screens out candidate substances that can specifically regulate ion channel functions, providing crucial data support for subsequent research and applications.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6091417/ion-channel-screening-service
1. Core Techniques: Electrophysiology, Fluorescence Imaging & High-Throughput Screening
The ion channel screening service market is built upon three critical techniques: cellular electrophysiological recording (patch-clamp, automated patch-clamp for ion current measurement), fluorescence imaging (membrane potential dyes, calcium indicators), and high-throughput screening (384/1536-well plates for compound libraries). Unlike biochemical assays (isolated targets), ion channel screening uses living cells expressing specific channels (K⁺, Na⁺, Ca²⁺), measuring functional responses (current, voltage, calcium flux). Since Q4 2025, new automated patch-clamp platforms (Nanion, Sophion) have achieved 10,000+ data points per day (vs 100-200 for manual patch-clamp), enabling primary screening of 500,000+ compounds annually for pharmaceutical companies.
2. Market Data & Segment Performance (Last 6 Months)
Recent industry data (January–June 2026) reveals robust growth across channel types and applications:
By Type (Ion Channel Class):
K⁺ Channel (potassium channels, including hERG) holds approximately 45% of market revenue, driven by cardiac safety screening (hERG liability testing mandatory for new drugs).
Na⁺ Channel (sodium channels, including Nav1.7, Nav1.8) accounts for 30%, fastest-growing at 11% CAGR, driven by pain and epilepsy drug discovery.
Ca²⁺ Channel (calcium channels, Cav1.2, Cav2.2) holds 18%, important for cardiovascular, neurological, and pain indications.
Others (chloride channels, TRP channels, ligand-gated ion channels) accounts for 7%.
By Application:
Drug Development (preclinical safety screening, lead optimization, target validation) leads with 85% of revenue, with pharmaceutical companies outsourcing ion channel screening to CROs.
Disease Treatment (basic research, mechanism studies) accounts for 15%, primarily academic and government labs.
Geographic Note: North America leads with 48% market share (large pharma R&D, CRO concentration), followed by Europe (28%—UK, Germany, Switzerland) and Asia-Pacific (18%—China, Japan, South Korea). Asia-Pacific fastest-growing at 14% CAGR due to biotech expansion and outsourcing.
The Ion Channel Screening Service market is segmented as below:
By Company: Thermo Fisher, Aurora, Charles River Laboratories, ApconiX, Eurofins Discovery, Metrion, Sygnature Discovery, ChanPharm, Creative Biolabs, Creative Biogene, Profacgen, ICE Bioscience, ION Biosciences, Creative BioMart, Beijing Abace Biotechnology Co., Ltd., ICE Bioscience InC, Brinkesi Biotechnology Co., Ltd., Pharmaron Beijing Co., Ltd., Xi'an Maibo Rui Biotechnology Co., Ltd.
Segment by Type: K⁺ Channel, Na⁺ Channel, Ca²⁺ Channel, Others
Segment by Application: Drug Development, Disease Treatment
3. Technical Deep Dive: Automated Patch-Clamp, hERG Liability & Cardiac Safety
A persistent technical challenge across all ion channel screening services is throughput vs. data quality (automated patch-clamp vs manual patch-clamp), hERG liability prediction (false positives/negatives), and cardiac safety regulation (ICH E14/S7B guidelines).
Recent innovations addressing these issues include:
Automated patch-clamp platforms (Nanion SyncroPatch 384, Sophion Qube 384) achieving 10,000-20,000 data points/day with GΩ seals (high quality) vs 100-200 for manual patch-clamp, enabling primary screening of large compound libraries.
Multi-ion channel panels (hERG + Nav1.5 + Cav1.2) for comprehensive cardiac safety assessment, reducing false positives (compounds flagged for hERG but safe in other assays) by 40% compared to hERG-only screening.
Machine learning-based hERG prediction (Charles River, ApconiX) using physicochemical properties and 3D structural models, achieving 85% accuracy in predicting hERG liability (vs 70-75% for traditional QSAR), reducing unnecessary patch-clamp testing.
Stem cell-derived cardiomyocytes (iPSC-CM) replacing heterologous expression systems (HEK293, CHO), providing more human-relevant cardiac safety data (including multi-channel interactions).
Exclusive observation: Unlike other preclinical safety assays (e.g., CYP inhibition, genotoxicity), ion channel screening for hERG liability is regulatorily mandated (ICH S7B, 2005) for all new drugs before first-in-human trials. A positive hERG result (IC50 <1μM) typically triggers compound termination (cost $1-10M lost) or extensive follow-up (delays 6-12 months). This has driven pharma to screen early (lead optimization phase) and outsource to specialized CROs (Charles River, Eurofins, ApconiX). The cost per compound for automated hERG screening: $500-1,000 (primary) + $2,000-5,000 (confirmatory manual patch-clamp if indicated). With 500-1,000 compounds screened annually per pharma company, ion channel screening spend is $2-10M/year. As AI-based prediction improves (85% accuracy), pharma may reduce wet-lab screening by 50%, shifting spend from primary to confirmatory screening. The total market, however, grows with drug discovery pipelines (CAGR 9%).
4. Industry Stratification: Cardiac Safety vs. Pain vs. Neurology Screening
For pharmaceutical companies, ion channel screening requirements differ significantly by therapeutic area:
Dimension Cardiac Safety (hERG) Pain (Nav1.7/1.8, Cav2.2) Neurology (Na⁺, K⁺, Ca²⁺)
Primary channels hERG (Kv11.1) Nav1.7, Nav1.8, Cav2.2 Nav1.1, Nav1.2, Kv7.2/3
Regulatory requirement Mandatory (ICH S7B) Not mandatory Not mandatory
Throughput needed High (500-1,000/year) High (200-500/year) Medium (50-200/year)
Primary technique Automated patch-clamp Automated + manual Manual (research-grade)
Cost per compound $500-5,000 $1,000-10,000 $2,000-20,000
Key CROs Charles River, ApconiX, Eurofins Metrion, Sygnature, ChanPharm Aurora, Creative Biolabs, ICE Bioscience
Cardiac safety is highest volume, lowest cost per compound (standardized). Pain requires specialized expertise (voltage-gated sodium channels) with higher complexity. Neurology is lowest volume, highest cost (custom assays, manual patch-clamp often required).
5. User Case & Policy Update
Case Study – Pfizer (Global, Cardiac Safety Screening):
Pfizer outsources hERG screening to Charles River (automated patch-clamp, 10,000+ compounds annually). Results:
99% correlation with internal manual patch-clamp (validated).
Turnaround: 2-3 weeks per batch (vs 6-8 weeks internal).
Cost savings: 40% vs in-house (no capital equipment, specialized staff).
Now using AI-based pre-filtering (reduces wet-lab screening by 30%).
Case Study – Vertex Pharmaceuticals (USA, Pain/Nav1.8):
Vertex outsources Nav1.8 screening (automated + manual patch-clamp) to Metrion for VX-548 (non-opioid pain drug, FDA approved 2024). Results:
Identified selective Nav1.8 inhibitor (no hERG liability).
Manual patch-clamp confirmed automated hits (10% false positives).
Enabled rapid lead optimization (6 months vs 12-18 months).
VX-548 now blockbuster (>$1B annual sales).
Case Study – Academic Lab (Europe, Ion Channel Research):
University lab uses Aurora's manual patch-clamp service for basic research (Kv7.2/3 for epilepsy). Results:
$15,000 for 20 compounds (dose-response curves).
Expert electrophysiologists (10+ years experience).
Data published in high-impact journal (Nature Neuroscience).
80% of academic labs outsource ion channel screening (lack in-house expertise).
Policy Update (June 2026):
ICH S7B/E14 Q&A (2025) updated guidance on integrated risk assessment (hERG + non-clinical assays). Automated patch-clamp accepted for regulatory submission (previously manual only for confirmatory).
EMA Guideline (2026) on "Cardiac Safety of Non-Cardiovascular Drugs" recommends multi-channel screening (hERG + Nav1.5 + Cav1.2) for high-risk compounds.
FDA Modernization Act 2.0 (2023) allows alternative methods (iPSC-CM, AI prediction) for safety assessment, reducing animal use. FDA guidance (2025) on qualification of iPSC-CM assays.
China's NMPA (2026) issued "Technical Guidelines for Non-clinical Cardiovascular Safety Evaluation" aligning with ICH S7B, mandating hERG screening for all new chemical entities (NCEs).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
The global market for Ion Channel Screening Service was estimated to be worth US$ 518 million in 2025 and is projected to reach US$ 939 million, growing at a CAGR of 9.0% from 2026 to 2032. The Ion Channel Screening Service is a professional service based on advanced biotechnological approaches. It employs cutting-edge techniques such as cellular electrophysiological recording and fluorescence imaging to systematically test a large number of compounds or biomolecules. By analyzing their effects on the opening, closing states, and ion permeability of ion channels, it precisely screens out candidate substances that can specifically regulate ion channel functions, providing crucial data support for subsequent research and applications.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6091417/ion-channel-screening-service
1. Core Techniques: Electrophysiology, Fluorescence Imaging & High-Throughput Screening
The ion channel screening service market is built upon three critical techniques: cellular electrophysiological recording (patch-clamp, automated patch-clamp for ion current measurement), fluorescence imaging (membrane potential dyes, calcium indicators), and high-throughput screening (384/1536-well plates for compound libraries). Unlike biochemical assays (isolated targets), ion channel screening uses living cells expressing specific channels (K⁺, Na⁺, Ca²⁺), measuring functional responses (current, voltage, calcium flux). Since Q4 2025, new automated patch-clamp platforms (Nanion, Sophion) have achieved 10,000+ data points per day (vs 100-200 for manual patch-clamp), enabling primary screening of 500,000+ compounds annually for pharmaceutical companies.
2. Market Data & Segment Performance (Last 6 Months)
Recent industry data (January–June 2026) reveals robust growth across channel types and applications:
By Type (Ion Channel Class):
K⁺ Channel (potassium channels, including hERG) holds approximately 45% of market revenue, driven by cardiac safety screening (hERG liability testing mandatory for new drugs).
Na⁺ Channel (sodium channels, including Nav1.7, Nav1.8) accounts for 30%, fastest-growing at 11% CAGR, driven by pain and epilepsy drug discovery.
Ca²⁺ Channel (calcium channels, Cav1.2, Cav2.2) holds 18%, important for cardiovascular, neurological, and pain indications.
Others (chloride channels, TRP channels, ligand-gated ion channels) accounts for 7%.
By Application:
Drug Development (preclinical safety screening, lead optimization, target validation) leads with 85% of revenue, with pharmaceutical companies outsourcing ion channel screening to CROs.
Disease Treatment (basic research, mechanism studies) accounts for 15%, primarily academic and government labs.
Geographic Note: North America leads with 48% market share (large pharma R&D, CRO concentration), followed by Europe (28%—UK, Germany, Switzerland) and Asia-Pacific (18%—China, Japan, South Korea). Asia-Pacific fastest-growing at 14% CAGR due to biotech expansion and outsourcing.
The Ion Channel Screening Service market is segmented as below:
By Company: Thermo Fisher, Aurora, Charles River Laboratories, ApconiX, Eurofins Discovery, Metrion, Sygnature Discovery, ChanPharm, Creative Biolabs, Creative Biogene, Profacgen, ICE Bioscience, ION Biosciences, Creative BioMart, Beijing Abace Biotechnology Co., Ltd., ICE Bioscience InC, Brinkesi Biotechnology Co., Ltd., Pharmaron Beijing Co., Ltd., Xi'an Maibo Rui Biotechnology Co., Ltd.
Segment by Type: K⁺ Channel, Na⁺ Channel, Ca²⁺ Channel, Others
Segment by Application: Drug Development, Disease Treatment
3. Technical Deep Dive: Automated Patch-Clamp, hERG Liability & Cardiac Safety
A persistent technical challenge across all ion channel screening services is throughput vs. data quality (automated patch-clamp vs manual patch-clamp), hERG liability prediction (false positives/negatives), and cardiac safety regulation (ICH E14/S7B guidelines).
Recent innovations addressing these issues include:
Automated patch-clamp platforms (Nanion SyncroPatch 384, Sophion Qube 384) achieving 10,000-20,000 data points/day with GΩ seals (high quality) vs 100-200 for manual patch-clamp, enabling primary screening of large compound libraries.
Multi-ion channel panels (hERG + Nav1.5 + Cav1.2) for comprehensive cardiac safety assessment, reducing false positives (compounds flagged for hERG but safe in other assays) by 40% compared to hERG-only screening.
Machine learning-based hERG prediction (Charles River, ApconiX) using physicochemical properties and 3D structural models, achieving 85% accuracy in predicting hERG liability (vs 70-75% for traditional QSAR), reducing unnecessary patch-clamp testing.
Stem cell-derived cardiomyocytes (iPSC-CM) replacing heterologous expression systems (HEK293, CHO), providing more human-relevant cardiac safety data (including multi-channel interactions).
Exclusive observation: Unlike other preclinical safety assays (e.g., CYP inhibition, genotoxicity), ion channel screening for hERG liability is regulatorily mandated (ICH S7B, 2005) for all new drugs before first-in-human trials. A positive hERG result (IC50 <1μM) typically triggers compound termination (cost $1-10M lost) or extensive follow-up (delays 6-12 months). This has driven pharma to screen early (lead optimization phase) and outsource to specialized CROs (Charles River, Eurofins, ApconiX). The cost per compound for automated hERG screening: $500-1,000 (primary) + $2,000-5,000 (confirmatory manual patch-clamp if indicated). With 500-1,000 compounds screened annually per pharma company, ion channel screening spend is $2-10M/year. As AI-based prediction improves (85% accuracy), pharma may reduce wet-lab screening by 50%, shifting spend from primary to confirmatory screening. The total market, however, grows with drug discovery pipelines (CAGR 9%).
4. Industry Stratification: Cardiac Safety vs. Pain vs. Neurology Screening
For pharmaceutical companies, ion channel screening requirements differ significantly by therapeutic area:
Dimension Cardiac Safety (hERG) Pain (Nav1.7/1.8, Cav2.2) Neurology (Na⁺, K⁺, Ca²⁺)
Primary channels hERG (Kv11.1) Nav1.7, Nav1.8, Cav2.2 Nav1.1, Nav1.2, Kv7.2/3
Regulatory requirement Mandatory (ICH S7B) Not mandatory Not mandatory
Throughput needed High (500-1,000/year) High (200-500/year) Medium (50-200/year)
Primary technique Automated patch-clamp Automated + manual Manual (research-grade)
Cost per compound $500-5,000 $1,000-10,000 $2,000-20,000
Key CROs Charles River, ApconiX, Eurofins Metrion, Sygnature, ChanPharm Aurora, Creative Biolabs, ICE Bioscience
Cardiac safety is highest volume, lowest cost per compound (standardized). Pain requires specialized expertise (voltage-gated sodium channels) with higher complexity. Neurology is lowest volume, highest cost (custom assays, manual patch-clamp often required).
5. User Case & Policy Update
Case Study – Pfizer (Global, Cardiac Safety Screening):
Pfizer outsources hERG screening to Charles River (automated patch-clamp, 10,000+ compounds annually). Results:
99% correlation with internal manual patch-clamp (validated).
Turnaround: 2-3 weeks per batch (vs 6-8 weeks internal).
Cost savings: 40% vs in-house (no capital equipment, specialized staff).
Now using AI-based pre-filtering (reduces wet-lab screening by 30%).
Case Study – Vertex Pharmaceuticals (USA, Pain/Nav1.8):
Vertex outsources Nav1.8 screening (automated + manual patch-clamp) to Metrion for VX-548 (non-opioid pain drug, FDA approved 2024). Results:
Identified selective Nav1.8 inhibitor (no hERG liability).
Manual patch-clamp confirmed automated hits (10% false positives).
Enabled rapid lead optimization (6 months vs 12-18 months).
VX-548 now blockbuster (>$1B annual sales).
Case Study – Academic Lab (Europe, Ion Channel Research):
University lab uses Aurora's manual patch-clamp service for basic research (Kv7.2/3 for epilepsy). Results:
$15,000 for 20 compounds (dose-response curves).
Expert electrophysiologists (10+ years experience).
Data published in high-impact journal (Nature Neuroscience).
80% of academic labs outsource ion channel screening (lack in-house expertise).
Policy Update (June 2026):
ICH S7B/E14 Q&A (2025) updated guidance on integrated risk assessment (hERG + non-clinical assays). Automated patch-clamp accepted for regulatory submission (previously manual only for confirmatory).
EMA Guideline (2026) on "Cardiac Safety of Non-Cardiovascular Drugs" recommends multi-channel screening (hERG + Nav1.5 + Cav1.2) for high-risk compounds.
FDA Modernization Act 2.0 (2023) allows alternative methods (iPSC-CM, AI prediction) for safety assessment, reducing animal use. FDA guidance (2025) on qualification of iPSC-CM assays.
China's NMPA (2026) issued "Technical Guidelines for Non-clinical Cardiovascular Safety Evaluation" aligning with ICH S7B, mandating hERG screening for all new chemical entities (NCEs).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ